EUVIMEDEUVIMED entdecken
VergleichsstudieKlinische Studie (Phase III)

Efficacy and Toxicity of [ 177 Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data

Vishnu Murthy, Andrew F Voter, Kathleen Nguyen, Martin Allen-Auerbach, Lucia Chen, Sydney Caputo, Elisa Ledet, Abraham Akerele, Abuzar Moradi Tuchayi, Courtney Lawhn-Heath, Tingchang Wang, Michael A Carducci und 8 weitere

Journal of Nuclear Medicine · 2024-11 · 65 (11) · 1740-1744

DOI: 10.2967/jnumed.124.267816 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 26.09.2024. Verfasst von Vishnu Murthy und 19 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles,…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Heterocyclic Compounds, 1-Ring, Lutetium, Dipeptides. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phase 3 VISION trial demonstrated that [177Lu]Lu-PSMA-617 prolonged progression-free survival and overall survival (OS) in prostate-specific membrane antigen [PSMA]-positive metastatic castration-resistant prostate cancer (mCRPC) patients who progressed on taxane-based chemotherapy and androgen receptor-signaling inhibitors (ARSIs). The U.S. expanded-access program (EAP; NCT04825652) was opened to provide access to [177Lu]Lu-PSMA-617 for eligible patients until regulatory approval was obtained. This study aimed to evaluate the efficacy and safety profile of [177Lu]Lu-PSMA-617 within the EAP and compare the results with those from the VISION trial.

Methods

Patients enrolled in the EAP at 4 institutions in the United States with available toxicity and outcome data were included. Outcome measures included OS, a prostate-specific antigen (PSA) response rate (RR) of at least 50%, and incidences of toxicity according to Common Terminology Criteria for Adverse Events version 5.0. Differences in baseline characteristics, outcome data, and toxicity between the EAP and VISION were evaluated using t testing of proportions and survival analyses.

Results

In total, 117 patients with mCRPC who received [177Lu]Lu-PSMA-617 within the EAP between May 2021 and March 2022 were eligible and included in this analysis. Patients enrolled in the EAP were more heavily pretreated with ARSI (≥2 ARSI regimens: 70% vs. 46%; P 0.05).

Conclusion

Patients with PSMA-positive mCRPC who received [177Lu]Lu-PSMA-617 within the EAP were later in their disease trajectory than VISION patients. Patients enrolled in the EAP achieved similar PSA RRs and OS and had a safety profile similar to that of the VISION trial patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHeterocyclic Compounds, 1-RingLutetiumDipeptidesNeoplasm MetastasisHumansMaleAgedUnited StatesMiddle AgedTreatment OutcomeAged, 80 and overProstate-Specific Antigen

Stichwörter der Autor:innen

EAPPSMA PETVISIONmCRPC

Substanzen

Heterocyclic Compounds, 1-RingLutetiumDipeptidesPSMA-617PluvictoProstate-Specific Antigen

Autor:innen und Institutionen

  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana.
  • Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.
  • Department of Biostatistics, Johns Hopkins School of Medicine, Baltimore, Maryland.

Zitieren

APA

Murthy, V., Voter, A. F., Nguyen, K., Allen-Auerbach, M., Chen, L., Caputo, S., Ledet, E., Akerele, A., Moradi Tuchayi, A., Lawhn-Heath, C., Wang, T., Carducci, M. A., Pomper, M. G., Paller, C. J., Czernin, J., Solnes, L. B., Hope, T. A., Sartor, O., Calais, J., & Gafita, A. (2024). Efficacy and Toxicity of [ 177 Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. Journal of Nuclear Medicine, 65(11), 1740-1744. https://doi.org/10.2967/jnumed.124.267816

Vancouver

Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, et al. Efficacy and Toxicity of [ 177 Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. Journal of Nuclear Medicine. 2024;65(11):1740-1744. doi:10.2967/jnumed.124.267816

BibTeX
@article{Murthy2024,
  author = {Murthy, Vishnu and Voter, Andrew F and Nguyen, Kathleen and Allen-Auerbach, Martin and Chen, Lucia and Caputo, Sydney and Ledet, Elisa and Akerele, Abraham and Moradi Tuchayi, Abuzar and Lawhn-Heath, Courtney and Wang, Tingchang and Carducci, Michael A and Pomper, Martin G and Paller, Channing J and Czernin, Johannes and Solnes, Lilja B and Hope, Thomas A and Sartor, Oliver and Calais, Jeremie and Gafita, Andrei},
  title = {Efficacy and Toxicity of [ 177 Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {11},
  pages = {1740--1744},
  doi = {10.2967/jnumed.124.267816}
}
Kostenlos starten →